'We are very pleased to welcome Bonnie to the Bruker board, and we especially value her entrepreneurial success, and her many years of genomics testing and diagnostics business expertise. She also has deep insights into oncology, hematology and immunology diagnostic tools and clinical workflows,' said
'I am honored to be appointed to the Bruker board, and I am looking forward to contributing to the success of such a dynamic and innovative company. I have admired the breakthrough work Bruker does in advancing life science and clinical research for many years, and I am thrilled to join such an impressive board,' said
'Our board regularly evaluates its composition to ensure it includes the appropriate skills, experience and perspectives to support Bruker's strategic direction. With Bonnie's addition, seven new Bruker directors will have joined Bruker's board in the past five years, including three women,' said
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
Forward Looking Statements
Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management's expectations for future financial and operational performance, business strategy, business outlook and Board performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to continued adverse changes in conditions in the global economy and volatility in the capital markets, the impact of the COVID-19 coronavirus outbreak and our ability to recover from its effects, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates, our material weaknesses in internal controls, our ability to successfully implement our restructuring initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital spending and government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the
Contact:
Tel: +1 (978) 663-3660 x1479
Email: investor.relations@bruker.com
(C) 2020 Electronic News Publishing, source